Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces the company will collaborate with ApexB.io and Magellan Rx Management to further research ...
Orexo AB (publ.), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) ") has today given notice to all holders of the Company's maximum SEK...
Orexo AB (publ.), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) has successfully issued senior unsecured callable floating rate bonds in the...
Orexo AB (publ.), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) has mandated ABG Sundal Collier AB to arrange a series of fixed income...
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that it is expecting to file its flagship pharmaceutical pipeline asset OX124 with the US ...
Q4 2020 highlights Total net revenues of SEK 159.2 m (238.1 last year, 196.2 m excl. Abstral® EU and US) Net earnings of SEK -49.6 m (38.9) EBITDA of ...
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the company has further strengthened the intellectual property (IP) for its flagship ...
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV®,...
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) has entered into an exclusive licensing agreement with Accord Healthcare, for the commercialisation of...
Accenture (NYSE: ACN) has helped the U.S. subsidiary of Swedish pharmaceutical company Orexo launch its first digital therapeutic, vorvida®, for...
(STO:ORX) (OTCQX:ORXOY) In connection with the publication of the Interim Report for Q3 2020, an updated guiding was shared for the full year 2020....
Q3 2020 highlights Total net revenues of SEK 150.3 m (231.2), 189.7 excluding Abstral® EU and US Net earnings of SEK -84.9 m (111.7), net earnings of ...
Orexo, a Swedish pharmaceutical company focused on improved pharmaceuticals and digital therapies, and Lyfebulb, a patient empowerment platform,...
Prior to the Annual General Meeting (AGM) in 2021, Orexo has appointed a Nomination Committee which represents approximately 44 percent of the number ...
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts, and media to attend a teleconference on Thursday October 1, at 3 pm...
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces it has filed a patent infringement action in the United States District Court for the...
Orexo and GoGoMeds have formed a partnership to make the scientifically-proven, digital therapies deprexis® and vorvida® available for the treatment...
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces it has received a "paragraph IV" patent certification notice from Sun Pharmaceutical...
Investing in diversification to drive future growth Q2 2020 highlights Total net revenues of SEK 179.1 m (201.2) EBITDA of SEK -9.0 m (60.4),...
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) announces today the US launch of the scientifically proven digital therapies deprexis® and vorvida®, for...
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces positive results from its human pharmacokinetic (PK) study of OX125. The study was a...
The number of shares and votes in Orexo AB (publ.) has changed as a result of the cancellation of 842,971 class C shares, which was resolved at the...
Today on 19 May 2020, Orexo AB (publ) held an extraordinary general meeting. The extraordinary general meeting passed the following resolutions....
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.